Patient P-03217
Therapy response
Stable
Tolerance
Improving
GI state
Improving
Inflammatory state
Improving
Nutritional resilience
Improving
Discontinuation risk
12%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 ONX-7 started — Baseline state S10
What changed?
Trajectory is tracking the baseline prediction.
Primary contributors, last 14 days
- Toxicity-16
- Inflammatory activity-6
- Treatment adherence+5
- GI instability-4
- Nutritional resilience+4
What helped?
No interventions yet.
LIFE OS recommendation
No intervention is indicated right now. The trajectory is stable relative to similar patients. See what worked for similar patients.
Daily trackers
Molecule settingsThe trackers this program marks as important, last 14 days vs the 14 before.
Energy level
Daily log6.3/10
improving · +0.3 vs previous 14 d
Stress level
Daily log4.2/10
improving · -0.4 vs previous 14 d
Pessimism score
Daily log4.1/10
stable · -0.1 vs previous 14 d
Sleep quality
Wearable43.7/100
improving · +1.4 vs previous 14 d
Libido
Daily log4.4/10
improving · +0.2 vs previous 14 d
HRV
Wearable32.4 ms
stable · +0.2 vs previous 14 d
Toxicity
Blood12.5/100
improving · -4.0 vs previous 14 d
This trajectory is doing well — what to keep, what to watch
Steering view →Heading towards restoration · 67 from the failing basin, 27 from restoration.
Good elements to keep
- Butyrate producers intacthidden · steering +7.5
- Protein (supports)perturbation · steering +5.8
- Daily walks resumedperturbation · steering +3.3
- Proteinsupporter · GI -3.6 next day
Main detractors to watch
- IL6 high-expression varianthidden · steering -7.3
- Poor-sleep weekperturbation · steering -3
- Low-HRV stretchperturbation · steering -2.7
- Dietary driftperturbation · steering -2.6
State influencers · digestive
Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.
- Protein-3.6supporter · 95%
- Histamine load+1.2no signal · 35%
- Dietary fat load+1no signal · 32%
- Lactose-0.5no signal · 15%
- Alcohol+0.3no signal · 15%
- Caffeine+0.1no signal · 15%
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Inflammatory signalling ↓40
- DNAIL6 -174 variant raises baseline inflammatory tone
- WearableHRV 32 ms, trending down
- Butyrate / short-chain fatty acid production ↓25
- MicrobiomeF. prausnitzii depleted
DNA
Fictional pharmacogenomic panel
- IL6 -174 G/CHigher inflammatory tone
- CYP2D6 Normal metabolizerExpected exposure
Microbiome
Shannon diversity 4.4 · butyrate capacity 65/100
- Akkermansia muciniphilaNormal
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisNormal
- Bifidobacterium longumNormal
- EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 30 ms
- Sleep
- 6.6 h
- Steps
- 7,553
- Resting HR
- 69 bpm
Daily log: GI score 23, nutritional resilience 64, adherence 97.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Keep meals regular; three to four moderate portions spaced through the day
- Include a cooked vegetable portion with each main meal
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Log the daily check-in; one line is enough
- Keep the current walking rhythm
- Keep the sleep window steady
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- No additional supplements this week
- Fictional demo item: continue vitamin D as before
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-03178 | 48% | S11 | GI-04 | improved | 54 |
| P-03374 | 46% | S19 | ME-01 | improved | 55 |
| P-03208 | 45% | S02 | BR-03 | improved | 57 |
| P-03144 | 44% | S16 | HY-01 | improved | 52 |
| P-03057 | 41% | S14 | NP-02 | improved | 64 |
| P-03179 | 41% | S05 | GI-04 | improved | 52 |
| P-03252 | 40% | S13 | SC-12 | improved | 68 |
| P-03484 | 38% | S07 | DT-01 | improved | 49 |
| P-03213 | 37% | S02 | DT-01 | improved | 59 |
| P-03215 | 37% | S16 | HY-01 | improved | 44 |
| P-03233 | 37% | S19 | DT-01 | improved | 47 |
| P-03255 | 37% | S01 | HY-01 | improved | 53 |